Evidence map›Paper›PMID 32865474›Full record

ArticleLeukemia & lymphoma2020

Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen.

Patrick Hagen, Anita D'Souza, Parameswaran Hari, Omar Davila, Mei-Jie Zhang, David H Vesole, Scott E Smith, Tulio E Rodriguez, Patrick J Stiff

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 11 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Patrick HagenStritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.ORCID 0000-0003-3428-1667
Anita D'SouzaDivision of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Parameswaran HariDivision of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Omar DavilaCIBMTR, Medical College of Wisconsin, Milwaukee, WI, USA.
Mei-Jie ZhangDivision of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
David H VesoleJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
Scott E SmithStritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.
Tulio E RodriguezDepartment of Hematology Oncology, Advocate Lutheran General Hospital, Chicago, IL, USA.
Patrick J StiffStritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.
Medical College of Wisconsin · USLoyola University Chicago · USAdvocate Lutheran General Hospital · USHackensack University Medical Center · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI FELICES, MARTIN · 2005 to 2025
$38.2M
Cure Sickle CellOT3HL147741 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI MARY EAPEN, Mary Maresca Horowitz · 2018 to 2026
$37.7M
Hematopopietic Stem Cell TransplantationU01AI069197 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2005 to 2026
$18.9M
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiencyU01AI126612 · NIAID · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S, PULSIPHER, MICHAEL A · 2017 to 2023
$8.5M
Immuno and Epigenetics of Hematopoietic Cell TransplantationR01CA218285 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2017 to 2026
$5.6M
The role of TCOF1 in germline predisposition to and in leukemic transformation of chronic myelomonocytic leukemiaR01CA152108 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Jing Zhang · 2011 to 2026
$5.4M
Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic DataR01AI128775 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JILL Allison HOLLENBACH, STEVEN JOHN MACK · 2017 to 2026
$4.5M
Identifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell DonorsR01HL131731 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PULSIPHER, MICHAEL A, SWITZER, GALEN E. · 2018 to 2022
$3.6M
Integrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantationR01CA215134 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BAKER, KEVIN S, MAJHAIL, NAVNEET S. · 2017 to 2022
$3.6M
Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA GenotypesR01HL129472 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI HSU, KATHARINE C · 2015 to 2019
$2.6M
NCI NIH HHS P01 CA111412NCI NIH HHS R01 CA152108NCI NIH HHS R01 CA215134NCI NIH HHS R01 CA218285NCI NIH HHS R01 CA231141NCI NIH HHS U24 CA076518NHLBI NIH HHS OT3 HL147741NHLBI NIH HHS R01 HL126589NHLBI NIH HHS R01 HL129472NHLBI NIH HHS R01 HL130388NHLBI NIH HHS R01 HL131731NHLBI NIH HHS R21 HL140314NHLBI NIH HHS U01 HL128568NHLBI NIH HHS U24 HL138660NIAID NIH HHS R01 AI128775NIAID NIH HHS U01 AI069197NIAID NIH HHS U01 AI126612
6 · The paper itself

Abstract

Melphalan at a dose of 200 mg/m

Indexed as

Hematopoietic Stem Cell TransplantationMultiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsBortezomibBusulfanFollow-Up StudiesHumansMelphalanTransplantation, AutologousTransplantation ConditioningBortezomibBusulfanMelphalanautologous stem cell transplantationbortezomibbusulfanmelphalanMultiple myeloma

Identifiers

PMID32865474
PMCPMC7786301
OpenAlexW3081943941

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.